Your browser doesn't support javascript.
loading
Combined inhibition of BET bromodomain and mTORC1/2 provides therapeutic advantage for rhabdomyosarcoma by switching cell death mechanism.
Srivastava, Ritesh K; Guroji, Purushotham; Jin, Lin; Mukhtar, M Shahid; Athar, Mohammad.
Afiliação
  • Srivastava RK; UAB Research Center of Excellence in Arsenicals, Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Guroji P; UAB Research Center of Excellence in Arsenicals, Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Jin L; UAB Research Center of Excellence in Arsenicals, Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Mukhtar MS; Department of Biology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Athar M; UAB Research Center of Excellence in Arsenicals, Department of Dermatology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Mol Carcinog ; 61(8): 737-751, 2022 08.
Article em En | MEDLINE | ID: mdl-35472745
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Rabdomiossarcoma / Proteínas Nucleares Tipo de estudo: Prognostic_studies Limite: Animals / Child / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Rabdomiossarcoma / Proteínas Nucleares Tipo de estudo: Prognostic_studies Limite: Animals / Child / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article